$KMB

Analyst recommendations: Kimberly-Clark, Palantir, Snap, Crowdstrike

Analysts updated recommendations for multiple companies. Kimberly-Clark (KMB) was downgraded to underperform with a higher price target. Palantir (PLTR) was upgraded to buy. Snap (SNAP) was upgraded to buy with a slightly lower target. Accenture (ACN) and others saw price target increases.

Original reporting
Published Aug 24, 2026, 9:53 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 10:26 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$KMB
Bearish
medium confidence
Mentioned
$KMB · $PLTR · $SNAP · $CRWD · $ACN · $ABNB
Relevance
5/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$KMBBearishMed
01

Why it matters

Aggregated rating changes provide modest signals; individual stock moves likely muted unless reinforced by other news.

02

Market read

Collective upgrades/downgrades may cause slight sector rotation but no major market mover.

03

What to watch

Potential earnings releases later in the day could dominate price action over analyst revisions.

Relevance 5/10Novelty 5/10Timing: morning release

Background

Morning analyst recommendation roundup covering multiple US-listed companies.

Company-level read

Ticker impact

$KMBBearishMedium confidence
Context

Baptista Research downgrades Kimberly-Clark to underperform and raises price target to $113.90.

Expected impact

Modest decline of 1‑2% in near term.

Evidence & confidence

Downgrade signals weaker outlook; price target increase is modest and may not offset.

$PLTRBullishMedium confidence
Context

William O'Neil & Co upgrades Palantir to buy from coverage suspended.

Expected impact

Potential 2‑3% rise if market reacts.

Evidence & confidence

New coverage and buy rating often lift sentiment.

$SNAPNeutralLow confidence
Context

Baptista Research upgrades Snap to buy from outperform and lowers price target to $6.80.

Expected impact

Flat to slight uptick, 0‑1% range.

Evidence & confidence

Target cut suggests concerns despite rating upgrade.

$CRWDBullishMedium confidence
Context

Jefferies maintains buy on Crowdstrike and raises price target to $230.

Expected impact

Possible 1‑2% gain.

Evidence & confidence

Higher target aligns with buy rating, could attract buyers.

$ACNNeutralLow confidence
Context

Citi maintains neutral on Accenture and raises price target to $190.

Expected impact

Little to no movement.

Evidence & confidence

No rating change, only target lift.

$ABNBBullishMedium confidence
Context

Bernstein maintains outperform on Airbnb and raises price target to $217.

Expected impact

Modest upside, ~1% potential.

Evidence & confidence

Higher target reinforces existing bullish view.

$ADIBullishMedium confidence
Context

Baird maintains outperform on Analog Devices and raises price target to $675.

Expected impact

Potential 2‑3% rise.

Evidence & confidence

Large target increase signals confidence.

$LHBullishLow confidence
Context

HSBC maintains hold on Labcorp and raises price target to $330.

Expected impact

Potential 1% rise.

Evidence & confidence

Hold rating limits upside.

Market effects

Analyst rating shifts may influence broader tech and industrial sectors.

US market sentiment may adjust modestly in early trade.

Limited to US-listed equities; no direct global macro effect.

Counterpoint

Some upgrades are offset by target cuts, suggesting caution despite rating changes.

Key entities

  • Baptista Research

    Provides rating updates for Kimberly-Clark and Snap.

  • William O'Neil & Co

    Upgraded Palantir to buy.

Related articles

$MRNAHighAI 9/10

Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage Trial

Moderna (MRNA) and Merck (MRK) announced their personalized melanoma vaccine, intismeran, combined with Keytruda, met Phase 3 trial goals, reducing cancer recurrence risk. Both companies' shares rose on the news. Full data will be presented at an upcoming medical meeting. Additional trials are ongoing for other cancers.

$MRNAMedAI 8/10

What you need to know about updated COVID vaccines following FDA approval

FDA approved updated COVID-19 vaccines from Moderna, Pfizer, and Sanofi targeting the XFG strain, which accounts for 40% of U.S. cases. Moderna's vaccine is approved for ages 6 months to 64 with conditions and all adults 65+. Pfizer's is for ages 5 to 64 with conditions and all adults 65+. Availability is expected in pharmacies, hospitals, and clinics. Insurance coverage is uncertain, but most plans may cover it. Experts emphasize vaccination to prevent severe disease, especially for high-risk g

$MRVLMedAI 8/10

Why Did Marvell Technology Stock Drop Today?

Marvell Technology (MRVL) reported fiscal Q2 2027 earnings, beating estimates with $0.94 EPS and $2.74B revenue. GAAP EPS was $0.33, up 50% YoY. Free cash flow was $474.3M. Guidance met analyst targets. Despite strong results, shares fell 8% due to high valuation at 84x trailing earnings.

$MRVLMedAI 8/10

What Trends Tell Investors To Do With Marvell Technology Right Now

Marvell Technology (MRVL) reported a 46% year-over-year increase in Data Center revenue to $2.17 billion, now 79% of total revenue. An expanded Google deal includes a warrant for 7% of shares. Shares are up 38% in a month, with analysts setting an average price target of $269.28. The company faces valuation concerns and concentration risk, but strong AI infrastructure demand supports its growth.

$MRVLHighAI 8/10

Marvell Technology shares are down over 8% after earnings details disappointed

Marvell Technology (MRVL) shares fell over 8% despite beating Q2 earnings estimates, as investors focused on the timing of revenue from its Google AI-chip deal. The company reported $0.94 adjusted EPS and $2.74B revenue, raising its fiscal 2027 and 2028 revenue outlook to $12B and $18B, respectively. Management highlighted strong AI-related bookings, but the market expected a faster payoff from the Google agreement.